Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

被引:5
|
作者
Lawson, Alexander [1 ]
Kamarajah, Sivesh K. [2 ]
Parente, Alessandro [2 ]
Pufal, Kamil [1 ]
Sundareyan, Ramanivas [3 ]
Pawlik, Timothy M. [4 ]
Ma, Yuk Ting [5 ]
Shah, Tahir [6 ]
Kharkhanis, Salil [3 ]
Dasari, Bobby V. M. [2 ,7 ]
机构
[1] Univ Birmingham, Birmingham Med Sch, Birmingham B15 2TT, England
[2] Queen Elizabeth Hosp, Dept HPB & Liver Transplantat, Birmingham B15 2TH, England
[3] Queen Elizabeth Hosp, Dept Radiol, Birmingham B15 2TH, England
[4] Ohio State Univ, Wexner Med Ctr, Dept Surg, Columbus, OH 43210 USA
[5] Queen Elizabeth Hosp, Dept Oncol, Birmingham B15 2TH, England
[6] Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, England
[7] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, England
关键词
hepatocellular carcinoma; transarterial embolisation; transarterial chemoembolisation; TRANSCATHETER ARTERIAL EMBOLIZATION; DRUG-ELUTING BEADS; CONVENTIONAL CHEMOEMBOLIZATION; BLAND EMBOLIZATION; TRIAL;
D O I
10.3390/cancers15123166
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patients treated with TACE/TAE, single versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has a comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs, which are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. Although hepatocellular carcinoma is increasingly common, debate exists surrounding the management of patients with unresectable disease comparing transarterial embolisation (TAE) or transarterial chemoembolisation (TACE). This study aimed to compare the outcomes of patients receiving TAE and TACE. A systematic review was performed using PubMed, Medline, Embase, and Cochrane databases to identify randomised controlled trials (RCTs) until August 2021. The primary outcome was overall survival (OS) and the secondary outcomes were progression-free survival (PFS) and adverse events. Five studies with 609 patients were included in the analysis. There was no statistically significant difference in the OS (p = 0.36) and PFS (p = 0.81). There was no difference in OS among patients treated with a single TACE/TAE versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] SORAFENIB ENHANCES EFFECTS OF TRANSARTERIAL CHEMOEMBOLISATION FOR HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Fu, Q.
    Zhang, Q.
    Bai, X.
    Hu, Q.
    Liang, T.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S117 - S118
  • [2] Transarterial chemoembolisation vs embolisation for hepatocellular carcinoma. A comparative audit
    Stigliano, R
    Morisco, F
    Chan, CW
    Cecilioni, L
    Leandro, G
    Burroughs, AK
    JOURNAL OF HEPATOLOGY, 2004, 40 : 83 - 83
  • [3] Transarterial Infusion Chemotherapy With and Without Embolisation in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis
    Zhao, Jing
    Li, Dapeng
    Shi, Yue
    Shi, Fengling
    Feng, Chengting
    Li, Wei
    Tao, Min
    Liang, Rongrui
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2017, 46 (05) : 174 - 184
  • [4] Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis
    Bogdanovic, Aleksandar
    Kovac, Jelena Djokic
    Zdujic, Predrag
    Djindjic, Uros
    Dugalic, Vladimir
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (05) : 1439 - 1446
  • [5] Commentary on 'Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis'
    Lu, Xin
    Liao, Yadi
    Liu, Yubin
    Shi, Feng
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (01) : 589 - 590
  • [6] Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma
    Li, Ningjie
    Yang, Ping
    Fang, Jun
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2022, 46 (09)
  • [7] Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis
    Duan, Ruihua
    Gong, Fen
    Wang, Yan
    Huang, Caixia
    Wu, Jiaming
    Hu, Leihao
    Liu, Min
    Qiu, Shijun
    Lu, Liming
    Lin, Yisheng
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [8] Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis
    Ruihua Duan
    Fen Gong
    Yan Wang
    Caixia Huang
    Jiaming Wu
    Leihao Hu
    Min Liu
    Shijun Qiu
    Liming Lu
    Yisheng Lin
    World Journal of Surgical Oncology, 21
  • [9] Effects of Debulking Surgery, Transarterial Embolisation (TAE) and Transarterial Chemoembolisation (TACE) on Quality of Life in Patients with Metastatic Ileal and Pancreatic Neuroendocrine Tumours (NETs)
    Sinclair, A.
    Tanno, L.
    Jarvis, E.
    Ramsey, E.
    Naheed, S.
    Armstrong, T.
    Takhar, A.
    Knight, J.
    Stedman, B.
    Modi, S.
    Bryant, T.
    Breen, D.
    NEUROENDOCRINOLOGY, 2020, 110 : 300 - 300
  • [10] Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
    H. Perfahl
    H. V. Jain
    T. Joshi
    M. Horger
    N. Malek
    M. Bitzer
    M. Reuss
    Scientific Reports, 10